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Abstract
Background: Human chorionic gonadotropin (hCG) has essential roles in pregnancy. Reports linking hCG in
non-trophoblastic tumors with poor patient prognosis has spurred interest in patho-physiological roles the
hormone might play.
Methods: The ability of hCG to prevent tumor cell death and sustain viability in the presence of chemotherapeutic
drugs was assessed and potential synergies with TLR ligands explored. hCG-induced up-modulation of genes
involved in chemoresistance was documented and targets validated by siRNA knock-down. Whether hCG could
drive collaboration between tumor cells and macrophages in the production of IL-6 and consequent chemoresistance
was assessed. The effects of concurrent anti-hCG immunization and chemotherapy on the growth of syngeneic murine
tumors were evaluated.
Results: hCG maintained basal levels of cytokine secretion by tumor cells exposed to chemotherapeutic drugs, and
enhanced viability and proliferation; pre-treatment with hCG also decreased apoptosis, as assessed by Annexin-V
binding and the cleavage of caspase 3. While co-incubation with hCG along with several TLR ligands mediated
heightened chemo-resistance, TLR-2/6 and TLR-9 ligands increased the phosphorylation of JNK, and TLR-2 and TLR-8
ligands the phosphorylation of ERK in presence of hCG and curcumin, providing evidence of tri-molecular synergy. The
hormone increased the transcription and/or expression of molecular intermediates (SURVIVIN, HIF-1α, PARP-1, Bcl-2,
c-FLIP, KLK-10, XIAP, c-IAP-1) associated with chemo-resistance and increased levels of stress modulators (PON2, HO-1,
HSP27 and NRF-2). siRNAs to SURVIVIN, NRF-2, HO-1 and HIF-1α attenuated hCG-mediated chemo-resistance.
hCG-conditioned tumor cell supernatants induced heightened secretion of IL-6 and TNF-α from peripheral blood
adherent cells and secreted IL-6 imparted chemo-resistance to naïve tumor cells. Co-administration of curcumin
along with an anti-hCG vaccine (hCGβ conjugated to Tetanus Toxoid (TT)) to mice carrying syngeneic tumors
resulted in significantly enhanced benefits on animal survival; synergy was demonstrated between anti-hCG
antibodies and curcumin in the reduction of tumor cell viability.
Conclusions: The data suggest that hCG, via direct as well as collaborative effects with TLR ligands and accessory
cell-secreted cytokines, mediates chemo-resistance in gonadotropin-sensitive tumors and outlines the potential
benefits of combination therapy.
Keywords: Human chorionic gonadotropin, Ectopic secretion, Prognosis, Chemoresistance, Immunotherapy
* Correspondence: rahul@nii.ac.in
Immunoendocrinology Lab, National Institute of Immunology, Aruna Asaf Ali
Marg, JNU Complex, New Delhi Delhi-110067, India
© 2015 Sahoo et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sahoo et al. BMC Cancer  (2015) 15:931 
DOI 10.1186/s12885-015-1938-x
Background
Chorionic gonadotropin, a glycoprotein hormone spe-
cific to primates, is possibly the first maternal indicator
of pregnancy. It extends the life of the corpus luteum to
elicit the continued secretion of progesterone [1], en-
ables implantation and trophoblast invasion, and sup-
ports angiogenesis [2, 3].
Several non-trophoblastic tumors have been shown to
express human chorionic gonadotropin (hCG) or its
constituent subunits [4–6]. Data are suggestive of hCG
playing a role in tumor growth by autocrine/paracrine
mechanisms. Incubation of bladder cancer cells with
hCGβ leads to dose-dependent proliferation [7], and
tumor-derived hCG is associated with unresponsiveness
to treatment and decreased survival [8, 9]. Further,
hCGβ-positive patients respond poorly to radiotherapy
[10] and its presence is associated with an aggressive
cancer phenotype and high metastatic potential [11].
Evidence for a pro-tumorigenic role for hCG has also
been provided by transgenic models; mice expressing
hCG develop gonadal neoplasia and extra-gonadal tu-
mors [12].
Chemo-resistance can result from numerous mecha-
nisms, including decreased intracellular drug concentra-
tions, an augmented ability to repair DNA damage or
endure stress, as well as the prevention of cell death.
TLR ligands [13], HIF-1α [14], Inhibitor of Apoptotic
Proteins [15] and pro-inflammatory cytokines [16] have
been linked with chemo-resistance and tumorigenesis.
The tumor microenvironment, including associated non-
transformed cells, can also contribute towards creation
of a pro-tumorigenic milieu [17].
Results obtained during this study support the notion
that exogenous gonadotropin can enhance tumor cell
growth and viability while additionally mediating chemo-
protection, and also identify potential molecular interme-
diates. Further, the data also suggests that third-party in-
fluences, such as enhanced signaling via toll-like receptors
and inflammatory cytokines secreted by non-transformed
accessory cells, can collaborate to enhance hCG-mediated
effects. Finally, evidence is provided to suggest that potent
anti-hCG vaccination, as an adjunct to conventional
chemotherapy, may hold promise in the treatment of




This study was carried out in strict accordance with pro-
tocols approved by the Institutional Animal Ethics Com-
mittee (IAEC) of the National Institute of Immunology
(IAEC Number: 231/10) and according to national and
international ethical guidelines.
Animals
Six week-old inbred female C57BL/6 mice were obtained
from the Small Animal Facility of the National Institute
of Immunology, New Delhi.
hCG, drugs, cell lines
Though recombinant hCG has been established to be
biologically potent in conventional assays (on reproduct-
ive tissues and processes) by several investigators, it con-
tains carbohydrates that are distinct from those on
native hCG due to variations in the extent of oligosac-
charide branching and sialylation. Since this study aimed
to evaluate the chemo-protective effects of hCG on
tumor cells (which have thus far not been described in
any detail), it was reasoned appropriate to employ native
hCG so as to expose cells to as natural a biological
stimulus as possible. Native hCG (Wyong Biologicals)
was subjected to physical (by SDS-PAGE and HPLC),
immunological (by a hCGβ-specific radioimmunossay
and Western blot) and biological (by radioreceptor assay
and Leydig cell bioassay) characterization; the prepar-
ation did not contain significant amounts of free hCGβ
and was independently assessed to express an activity of
≅ 11,000–13,000 IU/mg against relevant hCG standards,
the same range as reported for recombinant hCG when
the contribution of carbohydrates is taken into account.
hCG was employed over a range of concentrations
(10 μg/ml–100 ng/ml or ≅ 110 IU/ml–1.1 IU/ml).
Curcumin was obtained from Sanat Products; Tamoxi-
fen, Etoposide and 5-Fluorouracil (5-FU) were obtained
from Enzo Life Sciences. Human (Colorectal: COLO-
205 (CCL-222); Lung: ChaGo-K-1 (HTB-168)) and mur-
ine (Lewis Lung: LLC1 (CRL-1642); Melanoma: B16
(CRL-6323); Myeloma: SP2/O (CRL-1581)) cell lines
were obtained from ATCC and used within six months
of receipt or resuscitation. Human cell lines were au-
thenticated by STR at ATCC as per convention. All cell
lines were also authenticated by assessment of pheno-
typic, morphological and growth characteristics, and
were mycoplasma-free. Cells were cultured in RPMI
1640 (Life Technologies) or DMEM along with 10 %
fetal bovine serum (Biological Industries).
Effects of hCG on tumor cell viability, proliferation
B16, COLO-205, SP2/O and ChaGo-K-1 cells (5 × 104)
were incubated with hCG for 24 h. 50 μl of 3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT, Sigma) was then added and the reaction arrested
using DMSO. Absorbance was assessed at 550 nm. Data
(for this and subsequent MTT experiments) was plotted
as percentage viability compared with relevant controls.
Tumor cells pre-exposed to hCG for 24 h were incu-
bated with [3H]-Thymidine (0.5 μCi/well), followed by
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incubation for an additional 18 h. Cell-associated radio-
activity was assessed in a β-counter.
Effects of hCG on chemotherapeutic drug-induced loss of
tumor cell viability, apoptosis
COLO-205, ChaGo-K-1, SP2/O and LLC1 cells pre-
exposed to hCG for 24 h were treated with curcumin
(10 μM - 160 μM, Sigma) or tamoxifen (0.1 μM - 40 μM,
Sigma) for 24 h and 48 h respectively, and MTT assays
were carried out. In parallel experiments, reactivity of cells
to Annexin-V was determined by flow cytometry; briefly,
cells were incubated with Annexin-V-FITC (BD Biosci-
ences) for 15 m and run on a flow cytometer (BD-LSR;
BD Biosciences). Data was analysed using WinMDi 2.9
software.
Effect of hCG on activation of caspase-3
ChaGo-K-1 cells were incubated with hCG for 24 h and
subsequently with curcumin (40 μM) for 24 h. Conver-
sion of pro-caspase 3 to active (cleaved) caspase 3 was
assessed using an apoptosis array kit (R&D Systems). Re-
active spots were visualized by enhanced chemilumines-
cence (ECL; Biological Industries).
Combined effects of hCG and TLR ligands on
chemotherapeutic drug-induced loss of tumor cell viability
and on cell signaling
Cell Viability
COLO-205 cells pre-exposed to hCG for 24 h were incu-
bated with individual TLR ligands (Invivogen; TLR 1/2:
Pam3CSK4 (1 μg/ml); TLR2: HKLM (108 cells/ml),
TLR3: Poly I:C (10 μg/ml); TLR4: LPS (10 μg/ml); TLR5:
Flagellin (10 μg/ml); TLR2/6: FSL-1 (1 μg/ml), TLR7:
Imiquimod (5 μg/ml); TLR8: ssRNA40 (10 μg/ml);
TLR9: ODN2006 (5 μM)) for 24 h. Cellular viability
upon subsequent treatment with curcumin (at 40 μM)
was assessed at 24 h.
Cell Signaling
COLO-205 cells were incubated with hCG for 24 h prior
to incubation with individual TLR ligands (at the con-
centrations indicated above) for 24 h. Curcumin (at
40 μM) was then added and a further incubation carried
out for 24 h. Cells were then harvested and lysates
probed with monoclonal antibodies specific for total and
phosphorylated ERK and JNK (Santacruz Biotech) by
Western blot. Reactive moieties were visualized by en-
hanced chemiluminescence (ECL; Biological Industries).
Mediators of hCG-induced chemo-resistance
Identification
1 μg total RNA, obtained from ChaGo-K-1 cells pre-
exposed to hCG, was reverse transcribed into cDNA
using oligo-dT and reverse transcriptase (Promega).
Primers for amplification of human PARP-1, BCL-2, HIF-
1α, SURVIVIN, KLK-10, c-FLIP, different TLRs and β-
ACTIN (as control) are listed in Additional file 1: Figure
S1. For PCR, a 15 m denaturation step at 95 °C was
followed by 35 cycles of three steps each: 95 °C for 1 m,
annealing for 1 m, extension at 72 °C for 1 m, followed by
final extension at 72 °C for 10 m.
Cellular lysates, obtained from ChaGo-K-1 cells pre-
exposed to hCG, were electrophoresed and subsequently
transferred onto nitrocellulose membranes (mdi), and
probed with monoclonal antibodies specific to PARP-1,
BCL-2, HIF-1α, SURVIVIN, KLK-10 and c-FLIP. (Santa-
cruz Biotech); reactivity, subsequent to the addition of
secondary antibodies (Jackson ImmunoResearch), was
visualized by enhanced enzymatic chemi-luminescence.
Expression levels of the molecules subsequent to the in-
cubation of ChaGo-K-1 cells with hCG were also
assessed by flow cytometry; cells were permeabilized be-
fore incubation with specific antibodies for 1 h at 4 °C.
After addition of FITC-conjugated secondary antibodies
(Jackson ImmunoResearch), samples were run on a flow
cytometer and data analyzed by WinMDi 2.9 software.
ChaGo-K-1 cells were incubated with hCG for 24 h
and subsequently to curcumin (40 μM) for 24 h. Effects
on thirty five mediators involved in apoptosis and stress
regulatory responses were assessed using an apoptosis
array kit (R&D Systems). Reactive spots were visualized
by enhanced chemiluminescence.
Validation
ChaGo-K-1 cells were transiently transfected with either
control scrambled RNA (scRNA) or siRNA directed
against HIF-1Α, SURVIVIN, NRF-2 and HO-1 (Santacruz
Biotech). Briefly, scRNA or siRNA was diluted in trans-
fection medium to 30 pM, 60 pM or 120 pM. The solu-
tion was mixed with transfection reagent, incubated for
30 m at room temperature and overlaid on ChaGo-K-1
cells, following which an incubation was carried out for
6 h at 37 °C. Medium supplemented with 20 % FCS was
added and a further incubation carried out for 16 h.
Cells harvested from two parallel experiments were
assayed for decrease in mRNA (by semi-quantitative RT-
PCR) and protein (by Western blot) expression. The
ability of hCG to mediate chemo-resistance in trans-
fected cells was then assessed in a cell viability assay as
outlined above.
Assessment of the role of IL-6 in hCG-induced chemo-
resistance
ChaGo-K-1 and COLO-205 cells were incubated with
recombinant IL-6 (at 50 ng/ml; R&D Systems) for 6 h
and subsequently incubated with curcumin (40 μM) for
24 h. Viability was assessed by MTT.
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hCG tumor-conditioned medium (obtained upon incu-
bation of ChaGo-K-1 and COLO-205 with hCG for
24 h) was incubated with peripheral blood adherent cells
(PBACs; obtained upon plastic adherence of human
PBMCs) for 24 h. Levels of IL-6 and TNF-α in PBAC su-
pernatants were determined by ELISA (eBiosciences).
The ability of such PBAC supernatants to mediate resist-
ance to curcumin (at 40 μM) in naïve ChaGo-K-1 and
COLO-205 cells was assessed by MTT; the contribution
of elicited IL-6 to these effects was assessed using anti-
IL6 neutralizing antibodies (500 ng/ml; R&D Systems).
Effects of anti-hCG immunization and chemotherapy in
tumor-bearing mice
Vaccine formulation
hCGβ was conjugated to tetanus toxoid (TT) in a molar
ratio of 6:1 using the cross-linker sulfosuccinimidyl 6-
[3 )2 -pyridyldithio)-propionamido] hexanoate (LC-sul-
pho-SPDP; Pierce) as previously described [18]. The
hCGβ content in the conjugate was estimated by radio-
immunoassay. Briefly, increasing amounts (0.125 ng to
4 ng) of hCG or dilutions of the hCGβ-TT conjugate
were incubated at 4 °C for 18 h with a murine anti-
hCGβ specific monoclonal antibody in the presence of
125I-hCG (≅15,000 dpm; specific activity: 40–60 μCi/μg)
and 4 % normal horse serum. The antibody bound frac-
tion was precipitated by adding PEG 8000 (12.5 % final
concentration), separated by centrifugation at 1500 g at
4 °C for 20 m and counted for radioactivity. The concen-
tration of hCGβ in the conjugate was estimated with ref-
erence to the standard curve.
hCGβ-TT was adsorbed on Alhydrogel (Superfos;
1 mg protein/ml slurry) by incubation on an end-to-end
rocker at 4 °C for 16 h. Adsorption efficiency was greater
than 95 %.
Mycobacterium indicus pranii (MIP) was grown in
Middlebrook 7H9 media (BD Difco) supplemented with
10 % albumin-dextrose complex enrichment (BD Difco),
0.02 % glycerol, and 0.05 % Tween-80. Bacteria were
killed by autoclaving at 121 °C at a pressure of 15 lb/in2
for 20 m.
Intervention
Groups of female inbred C57BL/6 mice were subcutane-
ously implanted with syngeneic LLC1 cells (4 × 104 cells/
mouse). On the same day, mice received a subcutaneous
injection of 2 μg alhydrogel-adsorbed hCGβ-TT emulsi-
fied in Incomplete Freund’s Adjuvant (IFA; Life Tech-
nologies) along with MIP (108 cells; intramuscular),
hereafter referred to as immunotherapy. Three injections
were administered at monthly intervals. A second group
of animals was co-administered curcumin (2.5 mg/kg;
intra-peritoneal, thrice weekly) along with immunother-
apy. Additional groups of animals were treated with
curcumin, the vehicles, or were left untreated. Tumor
volumes (4/3πr3; r = (length + width)/4) were recorded at
periodic intervals.
Assessment of synergy between anti-hCG antibodies and
curcumin
In vitro experiments were conducted to demonstrate
whether anti-hCG antibodies and curcumin exerted syn-
ergistic effects on ChaGo-K-1 cells. Anti-hCG antibodies
(0–10 μg/ml) and curcumin (0–80 μM) were added
alone and in combination to ChaGo-K-1 cells and an in-
cubation carried out for 24 h. MTT assays were carried
out as described above. Whether the effects obtained
upon the combination of both moieties constituted syn-






where IC50 antibody and IC50 curcumin refer to respect-
ive concentrations resulting in 50 % inhibition in MTT
assays (when added alone), and C50 antibody and C50
curcumin refer to respective antibody and curcumin
concentrations (when added in combination) resulting in
50 % inhibition in MTT assays. Values of C.I. less than
one signify synergy, equal to one additivity, and greater
than one, antagonism [19].
Statistical Analysis
Data are expressed as arithmetic mean ± SD. Statistical
significance was assessed using the unpaired Student’s t-
test; the data distribution in the samples assayed was
normal. Animal survival was analyzed by the method of
Kaplan-Meier.
Results
Effects of hCG on tumor cell viability, proliferation
B16, COLO-205, SP2/O and ChaGo-K-1 cells were incu-
bated with hCG for 24 h; viability and proliferative re-
sponses were subsequently assessed. Human and murine
tumor cells exposed to hCG demonstrated increased via-
bility as well as increased rates of cell proliferation
(Fig. 1a and b).
Effects of hCG on chemotherapeutic drug-induced loss of
tumor cell viability
Based on the association of hCG with increased chemo-
resistance [9,20], whether hCG can directly induce
chemo-resistance in tumor cells was ascertained. hCG
pre-exposure resulted in a significant reduction in drug-
induced decrease in viability in both human and murine
tumor cells, though individual responses varied (Fig. 1c);
while hCG protected COLO-205 cells from only low to
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moderate concentrations of curcumin and tamoxifen,
SP2/O cells exposed to even high concentrations of tam-
oxifen remained significantly protected.
Effects of hCG on chemotherapeutic drug-induced apop-
tosis of tumor cells
Drug resistance is a multifactorial process and is charac-
terized by dysregulation of the equilibrium between cell
survival and apoptosis [21]. Whether hCG can effect
chemotherapeutic drug-induced apoptosis of tumor cells
was assessed; four tumor cell lines (COLO-205, SP2/O,
ChaGo-K-1, LLC1) and two drugs (curcumin, tamoxifen)
were employed. Pre-exposure to hCG dramatically re-
duced the binding of Annexin-V in cells incubated with
the drugs (Fig. 1d).
Incubation of ChaGo-K-1 cells with curcumin signifi-
cantly reduced levels of pro-caspase 3 compared to con-
trol cells, as expected. Significantly, pre-incubation with
hCG reduced levels of active (cleaved) caspase 3. In cells
incubated with both curcumin and hCG, levels of pro-
caspase 3 were higher and levels of active (cleaved) cas-
pase 3 lower compared to cells treated with curcumin
alone (Fig. 1e). These results suggest that hCG mediates
significant anti-apoptotic effects.
Fig. 1 hCG prevents chemotherapeutic drug-induced decrease in tumor cell viability and apoptosis. a Cell viability analysis on B16, COLO-205,
SP2/O and ChaGo-K-1 cells 24 h after hCG (10 μg/ml or ≅ 110 IU/ml) exposure. Means ± SEM of four independent experiments (with three
replicates) are shown. For each cell line, data has been individually normalized to cells plus medium. (*p < 0.003, @p < 0.03, #p < 0.04, $p < 0.0003
vs cells plus medium). b Proliferative responses of B16, COLO-205, SP2/O and ChaGo-K-1 cells 24 h after hCG exposure. Means ± SEM of three
independent experiments (with three replicates) are shown (*p < 0.0001, @p < 0.0001, #p < 0.0001, $p < 0.0001 vs cells without hCG). c Cell viability
analysis of COLO-205 (left top and bottom panels) and SP2/O (right top and bottom panels) cells after pre-incubation with either medium or hCG
for 24 h and then exposed to different concentrations of curcumin (for 24 h) or tamoxifen (for 48 h). VC: Vehicle control. Means ± SEM of four
independent experiments (with three replicates) are shown. For each cell line and for both control cultures and cultures containing hCG, data has
been individually normalized to cells plus vehicle control (VC). (*p < 0.04, #p < 0.009, $p < 0.0009 vs cells not exposed to hCG at the same drug
concentration). d Reactivity of ChaGo-K-1, COLO-205, SP2/O and LLC1 cells towards Annexin-V-PE by flow cytometry post-exposure to two
chemotherapeutic drugs (black profiles). In test cultures (green profiles), cells were exposed to hCG before addition of the drugs. Red profiles
indicate secondary antibody controls. Representative profiles of three independent experiments are shown. e Levels of pro-caspase 3 and caspase
3 in ChaGo-K-1 cells treated with hCG, curcumin or with hCG + curcumin. Cytochrome c (CYT C) was employed as loading control
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Effects of hCG on TLR expression and the combined
effects of hCG and TLR ligands on chemo-resistance
Increasing evidence points to a potential role for TLRs
in tumorigenesis and chemo-resistance [13, 22]. The
combined effects of hCG and TLR ligands on chemo-
resistance was assessed. Incubation with hCG led to in-
creases in mRNA and protein levels of TLR1, TLR3,
TLR8 and TLR9 in COLO-205 cells (Additional file 2:
Figure S2). Treatment of these cells with TLR ligands (in
the presence or absence of drugs) did not affect viability
over respective control cultures. COLO-205 cells pre-
exposed to hCG, then to individual TLR ligands and sub-
sequently to curcumin, demonstrated increased viability
in comparison to appropriate controls; interestingly, in
several instances, the addition of TLR ligands along with
hCG resulted in greatly enhanced chemo-protection
(Fig. 2a). Qualitatively similar effects were observed when
tamoxifen was employed as the chemo-therapeutic agent
(Additional file 3: Figure S3).
To gain further insight into the observed enhancement
in chemo-protective effects, the phosphorylation of ERK
and JNK upon the addition of hCG, individual TLR li-
gands and curcumin (alone and in combination) was
assessed; prominent data is discussed here. While individ-
ual addition of hCG and the TLR-9 ligand ODN2006 in-
duced JNK phophorylation, these moieties in combination
and in the additional presence of curcumin induced a syn-
ergistic increase. Similar synergism was observed when the
Fig. 2 hCG and TLR ligands synergistically enhance chemo-resistance. a Cell viability analysis on COLO-205 cells incubated with hCG (for 24 h),
individual TLR ligands (for 24 h) and curcumin (for 24 h) alone and in combination. H: hCG; P: Pam3CSK4; HK: HKLM; PI: Poly I:C; L: LPS; FL: Flagellin; F:
FSL-1; I: Imiquimod; ss: ssRNA40; O: ODN2006. Means ± SEM of three independent experiments (with three replicates) are shown. In each case, data has
been individually normalized to control cultures. (@p < 0.01 vs control cells, *p < 0.03 vs cells + curcumin, #p < 0.04, %p < 0.02, ^p < 0.0005, &p < 0.008 vs
hCG + curcumin). b Western blot analysis of the phosphorylation of JNK (left panel) and ERK (right panel) in COLO-205 cells exposed hCG, individual
TLR ligands and curcumin, individually or in combination, as indicated, in the manner described above
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TLR6 ligand FSL-1 was added along with hCG and curcu-
min. While hCG induced the phosphorylation of ERK and
ligands for both TLR-2 and TLR-8 (HKLM and ssRNA40
respectively) were ineffective (at 48 h post stimulation),
hCG acted in synergy with both these ligands to enhance
ERK phoshorylation. The addition of curcumin to hCG
and ssRNA40 resulted in further enhancement (Fig. 2b).
To summarize, both bimolecular (involving some TLR li-
gands and hCG) as well as tri-molecular (involving some
TLR ligands, hCG and curcumin) synergies were observed,
the potential significance of which is discussed below.
Identification and validation of potential mediators of
hCG-induced chemo-resistance
Message and expression levels of molecules known to be
associated with chemo-resistance and also known to be
modulated by hCG (for the most part, in reproductive
tissues) were evaluated. mRNA and protein levels of
PARP-1, BCL-2, HIF-1α, SURVIVIN, KLK-10 and c-
FLIP increased in ChaGo-K-1 cells upon hCG treatment
(Fig. 3a-c). Several of these factors were transcriptionally
and translationally upregulated in COLO-205 cells upon
hCG treatment as well (Additional file 4: Figure S4). A
Fig. 3 hCG increases mRNA and expression levels of molecules associated with chemo-resistance, apoptosis and cell stress in tumor cells.
a Semi-quantitative RT-PCR of molecules associated with chemo-resistance upon incubation of ChaGo-K-1 cells with medium or medium supplemented
with hCG. β-ACTIN was employed as loading control. b Western blot of molecules associated with chemo-resistance upon incubation of ChaGo-K-1 cells
with medium or medium supplemented with hCG. β-ACTIN was employed as loading control. c Flow cytometric analysis of molecules associated with
chemo-resistance upon incubation of ChaGo-K-1 cells with medium or medium supplemented with hCG. Cells were permeabilized and stained with
the respective antibodies. Filled red profiles indicate secondary antibody controls, green profiles indicate control cells and blue profile cells incubated
with hCG. Data in A-C representative of four independent experiments. d Array dot blot analysis on ChaGo-K-1 cells incubated with medium, hCG,
curcumin, or with hCG + curcumin. Expression levels of proteins associated with inhibition of apoptosis, chemo-resistance and protection from cell stress
are shown. Cytochrome c (CYT C) was employed as loading control
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dot blot array capable of detecting thirty five apoptosis-
and stress regulatory response-related proteins was
employed to confirm and extend these findings.
ChaGo-K-1 cells incubated with hCG demonstrated in-
creases in the levels of cIAP-1, XIAP and SURVIVIN
(inhibitors of apoptotic proteins), HIF-1α, HO-1 (asso-
ciated with chemo-resistance and tumorigenesis), and
PON2 and HSP27 (associated with protection from cell
stress). Incubation with curcumin alone caused observ-
able decreases in the levels of several of these mole-
cules. Significantly, levels of these chemo-protective
molecules remained high even in cells treated with
apoptosis-inducing doses of curcumin in the presence
of hCG (Fig. 3d).
HIF-1α, HO-1 and SURVIVIN were selected for fur-
ther study, based on the weight of evidence linking them
with chemo-resistance and tumorigenesis [23]; further,
NRF-2 was also chosen, given its role up-stream of these
molecules [24]. Specific siRNAs designed to target these
molecules decreased transcript and protein levels in a
dose-dependent manner (Fig. 4a). As anticipated, de-
creased expression of SURVIVIN and HO-1 levels were
observed when siRNA against HIF-1α and NRF-2 was
respectively employed (Additional file 5: Figure S5).
To investigate the roles of HIF-1α, HO-1, NRF-2
and SURVIVIN in hCG-induced chemo-resistance,
ChaGo-K-1 cells transfected with individual siRNAs
were incubated with hCG and later exposed to either
tamoxifen or curcumin. Silencing the proximal factor
NRF-2 and the distal factor SURVIVIN either fully or
substantially reversed the protection rendered by hCG
against both drugs. Addition of siRNA to HO-1 or
HIF-1α, on the other hand, had more modest or min-
imal effects, depending on the nature of the toxic in-
sult (Fig. 4 b-e).
Role of IL-6 derived from non-transformed cells in
hCG-induced chemo-resistance
Previous literature documents the production IL-6 (a
cytokine associated with the development of chemo-
resistance [16, 25]) by macrophages under the influence
of tumor-derived factors [26]. The ability of recombinant
IL-6 to induce protection against curcumin was verified
on COLO-205 and ChaGo-K-1 (Fig. 5a). hCG was
Fig. 4 Down-modulation of SURVIVIN, HIF-1α, HO-1 and NRF-2 decreases hCG-induced chemo-resistance. a mRNA levels by semi-quantitative
RT-PCR (left panel) and protein levels by Western blot (right panel) of SURVIVIN, HIF 1-α, HO-1 and NRF-2 upon transfection of respective siRNAs
in ChaGo-K-1 cells. scRNA: scrambled RNA control. β-ACTIN was employed as loading control. b-e Cell viability analysis of ChaGo-K-1 cells
individually transfected with siRNAs against SURVIVIN, HIF 1-α, HO-1 and NRF-2 incubated with hCG and later exposed to (b, d) tamoxifen or
(c, e) curcumin. scRNA: scrambled RNA control. For b-e, means ± SEM of four independent experiments (with three replicates) are shown. In each
case, data has been individually normalized to control cultures. (&p < 0.0003 vs drug + hCG; *p < 0.003, #p < 0.0003, $p < 0.03 vs hCG + respective
scRNA + respective drug)
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incapable of inducing the secretion of IL-6 or TNF-α
from tumor cells (data not shown) or from PBAC
(Fig. 5b). However, heightened levels of IL-6 and TNF-α
were observed in supernatants of human PBACs incu-
bated with hCG-primed tumor conditioned medium
(Fig. 5b). Such PBAC supernatants, when incubated with
naive COLO-205 and ChaGo-K-1 cells, induced resist-
ance to curcumin-mediated loss of viability; anti-IL-6
neutralizing antibodies negated this protective effect
(Fig. 5c). These results suggest chemo-resistance can
arise as a consequence of the interaction between tumor
cells and normal cells, with hCG being the intermediary.
Effects of anti-hCG immunization and chemotherapy in
tumor-bearing mice
Anti-hCG vaccination restricts the growth of murine tu-
mors in vivo [27–29], data which validates the use of
surrogate syngeneic immunization protocols.
All C57BL/6 mice injected with LLC1 cells generated
tumors; administration of the vehicles had no effect on
tumor incidence or volume. In animals receiving either
immunotherapy (the hCGβ-TT vaccine) or chemotherapy
(curcumin), tumor incidence was reduced to 50 %; tumors
that did arise demonstrated significantly smaller volumes,
as assessed on Day 57 post-tumor implantation. The
Fig. 5 hCG-driven collaborative elicitation of IL-6 and consequent chemo-resistance. a Cell viability analysis on COLO-205 (top panel) and
ChaGo-K-1 (bottom panel) cells pre-incubated with recombinant IL-6 and later exposed to curcumin. Means ± SEM of four independent experiments
(with three replicates) are shown. For each cell line and for both control cultures and cultures containing hCG, data has been individually normalized
to cells plus vehicle control (VC).(*p < 0.0009, ~p < 0.006, #p < 0.0001, %p < 0.03, &p < 0.0001, >p < 0.0004 vs cells not exposed to IL-6 at the same drug
concentration). b Levels of TNF-α and IL-6 in supernatants of peripheral blood adherent cells (PBACs) exposed to hCG or to tumor-conditioned
medium (TCM) derived from either control or from hCG-pre-incubated COLO-205 (left top and bottom panels) and ChaGo-K-1 (right top and bottom
panels) cells. The effects of concurrent incubation with anti-hCG antibodies or isotype control (I.C.) antibodies are also shown ($p < 0.0001,*p < 0.0002,
%p < 0.0004, #p < 0.0008). c Assessment of the ability of IL-6 (in supernatants of PBACs obtained upon incubation with hCG tumor-conditioned
medium) to mediate resistance to curcumin in COLO-205 (left panel) and ChaGo-K-1 (right panel) cells. The relative efficacies of anti-IL-6 antibodies
and isotype control (I.C.) antibodies to neutralize the protective effects of IL-6 are also shown. The right-most bars in each graph represent controls
cultures in which only medium was dispensed to which data has been individually normalized. (*p < 0.0003, #p < 0.001). For b and c, means ± SEM of
three independent experiments (with three replicates) are shown
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consequences of combination immunotherapy and
chemotherapy on tumor growth were also subsequently
assessed. Co-administration had effects on multiple pa-
rameters; while tumor incidence was further reduced,
mean tumor volumes were significantly lower than
those observed upon individual immunotherapy or
chemotherapy. Further, there was an extended lag
period before the appearance of tumors (Fig. 6 a, b).
Kaplan-Meier analysis re-iterated the benefits of the
combinatorial approach on animal survival. Mortality
rates in animals treated with the vehicles were similar
to those observed in untreated animals, with all animals
in both groups succumbing by Day 70. Curcumin treat-
ment and anti-hCG vaccination significantly improved
survival over these control groups when individually ad-
ministered; there was no difference in animal survival be-
tween chemotherapy and immunotherapy. Importantly,
treatment with immunotherapy in combination with
chemotherapy led to significant improvements in survival
over both treatments administered individually (Fig. 6c).
Synergy between anti-hCG antibodies and curcumin
The simultaneous addition of anti-hCG antibodies
and curcumin on ChaGo-K-1 cells induced significant
Fig. 6 Enhanced anti-tumor effects of combination chemotherapy and anti-hCG immunotherapy. a Kinetics of tumor growth in individual C57BL/
6 mice (n = 8) implanted with syngeneic LLC1 tumor cells. Data for control animals (treated with saline or vehicles) and for animals receiving anti-hCG
immunotherapy, curcumin or immunotherapy + curcumin is shown. b Tumor volumes on Day 57 post-tumor cell implantation in C57BL/6 mice im-
planted with syngeneic LLC1 tumor cells treated with immunotherapy, curcumin or immunotherapy + curcumin. Each symbol represents an individual
animal (*p < 0.001, @p < 0.0001, #p < 0.0002). c Kaplan-Meier analysis for C57BL/6 mice implanted with syngeneic LLC1 tumor cells receiving curcumin,
immunotherapy or immunotherapy + curcumin. Control animals received either saline or vehicles. p < 0.0019, saline vs curcumin; p < 0.0228,
saline vs immunotherapy; p < 0.0019, saline vs curcumin + immunotherapy; p < 0.0013, vehicles vs curcumin; p < 0.022, vehicles vs
immunotherapy; p < 0.0013, vehicles vs immunotherapy + curcumin; p < 0.018, curcumin vs immunotherapy + curcumin; p < 0.007, immunotherapy
vs immunotherapy + curcumin
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inhibitory effects over the addition of individual moi-
eties (Additional file 6: Figure S6A).
A graphical representation of the analysis for the de-
termination of the Combination Index (C.I.) is depicted
in Additional file 6: Figure S6B. IC50 values for curcumin
and anti-hCG antibodies are plotted as (IC50 antibody,
0), (0, IC50 curcumin) and C50 antibody, C50 curcumin
(for two representative data points) as dot plots. For the
two data points, C.I. values were 0.699 (red) and 0.711
(green), values which constitute evidence of synergy, be-
ing less than one.
Discussion
Growing evidence suggests that tumors secrete factors
that can affect either tumor cells themselves or cells in
the microenvironment to regulate growth and progres-
sion [17].
The demonstration of hCG in several non-trophoblastic
tumors such as pancreatic and biliary cancer [4], urothelial
cancer [5] and lung cancer [6] has spurred interest in
patho-physiological roles the hormone might play, par-
ticularly since elevated levels of the hormone are often
correlated with higher metastatic potential [11], unrespon-
siveness to drugs and poor patient prognosis [8, 9, 20].
Though the increase in the viability and proliferation of
tumor cells upon exposure to exogenous hCG in this
study are in line with similar findings by previous investi-
gators, the molecular mechanisms linking the hormone to
chemo-resistance (a major determinant of poor prognosis)
have not been investigated in any detail, save for a study
demonstrating the ability of hCG to induce resistance to
cisplatin in ovarian cancer cells [30].
The current study provides substantial evidence of the
chemo-protective effects of hCG. While tamoxifen has
been widely employed in the treatment of human cancer,
several studies have demonstrated the toxic effects cur-
cumin on tumor cells of various lineages; it is an antioxi-
dant and anti-inflammatory agent, and an inhibitor of
NF-kappa B. Interestingly, curcumin has also been dem-
onstrated to enhance sensitivity of tumor cells to a var-
iety of drugs and hence has been considered a
“chemosensitizing” agent [31]. hCG also reduced etopo-
side- and 5-FU- mediated loss of tumor cell viability
(Additional file 7: Figure S7A). Two additional read-outs
supported the idea that hCG has trophic effects on
tumor cells. Firstly, hCG ameliorated the suppression
of proliferation (as assessed by the uptake of [3H]-Thy-
midine) induced by curcumin, tamoxifen and 5-FU
(Additional file 7: Figure S7B). Secondly, while 5-FU
caused a decrease in basal levels of secretion of IL-8 (a
cytokine associated with tumorigenesis) from COLO-
205 cells, pre-incubation with hCG prevented such de-
creases (Additional file 7: Figure S7C). Since the drugs
employed in this study act via different mechanisms to
induce cytotoxicity, the study demonstrated that the
protective effects of hCG were wide-ranging, generic
and not restricted to a specific pathway.
While several genes have been implicated in chemore-
sistance, it was not the primary aim of this manuscript
to assess the effects of hCG on them all. Rather, this
study had a more focussed objective. The genes selected
for study in this work were primarily chosen on the basis
of two criteria: Firstly, all had previously been shown to
be modulated by hCG (in reproductive tissues but not in
cancer cells) and secondly, all had also been shown to
play a role in chemoresistance (mediated by moieties
other than hCG, either in reproductive tissues or in can-
cer cells). Application of these dual criteria resulted in
the selection of genes that were of a more generic na-
ture, not associated with a particular drug.
Incubation of tumor cells with hCG resulted in an in-
creased expression of c-FLIP, an endogenous inhibitor of
caspase 8. Since caspase 8 acts to up-regulate levels of
caspase 3, these results are in line with the observed de-
crease in the conversion of pro-caspase 3 to caspase 3
upon incubation of tumor cells with hCG. Increase in
BCL-2 upon hCG treatment in human colorectal and
lung cancer cells in the current study suggests that in-
hibition of the mitochondrial pathway of apoptosis also
possibly contributes to hCG-induced protection from
drug-induced tumor cell death, although this postulate
awaits formal verification.
hCG-induced effects on tumor cells appear to be the
result of multiple collaborative pathways. Down-stream
events can be postulated to occur post the proliferative
responses induced by hCG, since uncontrolled prolifera-
tion can increase oxidative stress, endoplasmic reticulum
(ER) stress and genomic instability-induced stress [32], a
likely result of which is apoptosis. Tumor cells respond
to such threats by up-modulation of ER stress regulators
like BCL-2, HIF-1α, PARP-1, HSP27, HO-1 and PON2,
all molecules shown to be up-modulated in tumor cells
upon the addition of hCG in this study; hCG also en-
hanced levels of IAPs such as SURVIVIN, cIAP-1 and
XIAP, known contributors to chemo-resistance. These
results imply that hCG may act as an anti-stress regula-
tor. The reversal of hCG-induced chemo-resistance in
cells depleted of NRF-2 (a transcription factor upstream
of HIF-1α and HO-1) and SURVIVIN in the current
study suggests that hCG can exert its influence on both
the proximal and distal ends of the apoptotic pathway.
The fact that hCG provides protection against drugs
which act via distinct mechanisms, as well against nutri-
ent exhaustion-induced death (data not shown), sup-
ports this conclusion.
Increasing evidence links TLR signalling with tumori-
genesis and the development of chemo-resistance [13,
22, 33]. In the current study, hCG increased the
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transcription and expression of TLR1, TLR3, TLR8 and
TLR9; interestingly, and the combined addition of hCG
with ligands for these TLRs (along with many others) re-
sulted in enhanced chemo-protective effects, beyond
those observed when hCG and the TLR ligands were in-
dividually employed. Because of the nature of some of
the ligands employed in this study as well as the fact that
some TLRs exist as signalling heterodimers, the results
may not be always attributable to individual TLRs. For
example, while HKLM appears to be an exclusive TLR2
agonist, Pam3CSK4 binds the TLR1/TLR2 dimer and
FSL-1 the TLR2/TLR6 dimer; outcomes using Pam3CSK4
and FSL-1 may therefore be a consequence of TLR2 trig-
gering. Regardless of these fine distinctions and in light of
the data with other ligands, it does appear that NF-κB
may comprise a central event, where both MyD88-
dependent (all TLRs with the exception of TLR3) and
TRIF-dependent (TLR3 and TLR4) pathways converge
[34]. The global enumeration of genes that are modulated
in response to dual ligand stimulation is underway.
Data obtained upon analysis of signalling events in
cells exposed to hCG, TLR ligand and chemotherapeutic
drug is strongly suggestive of tri-molecular synergy in
some instances. Of particular interest in this regard were
signalling synergies between hCG and the TLR9 ligand
ODN2006 for JNK phosphorylation and between hCG
and the TLR8 ligand ssRNA40 for ERK phosphorylation,
given the fact that both TLR8 and TLR9 were upmodu-
lated by hCG. Based on currently available and emerging
data, the following scenario can be envisaged: Assault by
chemotherapeutic drugs induces the release endogenous
TLR ligands from cells as they die. In the cells that sur-
vive, hCG-mediated up-modulation of TLR expression
contributes to enhanced hCG-TLR intracellular signal-
ling; the consequence of these events is the creation
of an environment characterized by heightened levels
of stress regulatory mediators which drive chemo-
resistance (Additional file 8: Figure S8). The sustained
activation of MAP kinase signalling pathways, which
may contribute to these events, may have further im-
plications as well; tumorigenesis is often characterized
by enhanced and sustained signalling via these path-
ways [35, 36]. Indeed, inhibition of the JNK and ERK
signaling pathways are considered valid therapeutic
strategies. Ligands capable of triggering such events
in tumor cells (particularly those not arising as a re-
sult of mutational events) are of obvious interest.
Of the many accessory cells known to augment tumor
progression, macrophages are of particular interest [37].
Previous studies have suggested a role for IL-6 in the de-
velopment of chemo-resistance [16, 25]. Tumor-derived
versican (a proteoglycan which sequesters chemokines
and acts as a chemo-attractant for inflammatory cells in
the tumor milieu) can stimulate resident macrophages
to secrete IL-6 and TNF-α in a TLR-2 dependent man-
ner [26]. Previous work in the lab has demonstrated the
ability of hCG to enhance the secretion of versican from
tumor cells, resulting in the release of these inflamma-
tory cytokines in a TLR-2 dependent manner (data not
shown). The current work demonstrates that the en-
hanced levels of macrophage-elicited IL-6 can mediate
chemo-resistance. These results suggest that, in addition
to mediating direct chemo-protective effects, hCG can
also initiate cross-talk between tumor cells and macro-
phages to induce the generation of chemo-protective
cytokines.
On-going studies have established that implantation of
tumor cells in mice transgenic for βhCG results in in-
creased tumor incidence and higher tumor volume. In
addition, transcription of several of the genes identified
in this study is up-modulated in tumors implanted in
these animals (data not shown).
In view of the known and suspected roles of hCG in
tumorigenesis, anti-hCG vaccination is increasingly con-
sidered an attractive option. A vaccine based on the C-
terminal region of hCG induced beneficial effects in
patients of colorectal cancer [38]. Previous studies have
also described the ameliorating effects on the reproductive
axis of anti-hCG immunization in hCGβ transgenic mice
which express ovarian hyperplasia and pituitary tumors
[39]. Most other work in the area involves the use of sur-
rogate murine systems [27–29]. One of these studies [28]
provided evidence for adjuvantic and anti-tumor effects of
MIP in anti-hCG vaccination, work that was based on pre-
vious published reports on the anti-tumor potency of MIP
in mice [40] and in humans [41]. While IFA has often
been employed as an adjuvant in humans with encour-
aging results [42], the other components in the formula-
tions employed in this study have been approved for use
in humans, with an analogous vaccine having previously
demonstrated the ability to break tolerance towards hCG
and exert anti-fertility effects in women [43].
Concurrent chemotherapy is believed to potentiate
immunotherapeutic responses, possibly by increasing
inflammation in the target area [44]. Conversely, im-
munotherapy, particularly directed against a soluble, po-
tential tumor-promoting moiety like hCG that induces
chemo-resistance, can potentially enhance the thera-
peutic efficacy of chemotherapy as well. The current
study, using a validated murine model, suggests that the
combination of chemo-therapy and immunotherapy of-
fers distinct advantages; add-on anti-hCG immunother-
apy improved three critical parameters of tumorigenesis
in animals treated with curcumin: tumor incidence,
tumor volume and animal survival. Quite conceivably,
such combination regimens would permit reduction in
chemotherapeutic drug dose, thereby serving to also
ameliorate associated toxicities.
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Conclusions
Tumor-derived gonadotropin has been associated with
reduced survival. The novelty of the current study lies in
the elucidation of some of the mechanistic details of the
hormone’s tumor-protective effects in the face of drug
assault. The data uniquely demonstrates that hCG elicits
pro-survival signals which interfere with the apoptotic
cascade and can enhance the ability to counter cellular
stress. That the additional presence of TLR ligands was
shown to greatly enhance chemoresistance supports the
testable, hitherto unconsidered postulate that dying
tumor cells (a potential source of endogenous TLR li-
gands) may engender increased resistance in tumor cells
that survive. The collaborative elicitation of IL-6 from
monocytes presents an alternative mechanism of hCG-
mediated chemo-resistance. The data also suggest that
combination immunotherapy-chemotherapy protocols,
using moieties and materials already in human use, may
result in substantial beneficial effects in patients carrying
gonadotropin-sensitive tumors.
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